Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

gsk vaccines s.r.l. - corynebacterium diphtheriae crm-197 protein, neisseria meningitidis serogroup c, stamme c11, oligosaccharid - injektionsvæske, suspension, fyldt injektionssprøjte - 10 mikrogram

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

gsk vaccines s.r.l. - corynebacterium diphtheriae crm-197 protein, neisseria meningitidis serogroup c, stamme c11, oligosaccharid - injektionsvæske, suspension, hætteglas - 10 mikrogram

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

gsk vaccines s.r.l. - corynebacterium diphtheriae crm-197 protein, neisseria meningitidis polysaccharid serogruppe c, stamme c11 - pulver og solvens til injektionsvæske, suspension - 19+10 mikrog/dosis

Den Europæiske Union - dansk - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuri, paroxysmal - immunosuppressiva - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hexal a/s - ciprofloxacin - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - ciprofloxacinhydrochlorid, vandfrit - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka sverige ab - ciprofloxacinhydrochlorid (monohydrat) - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - ciprofloxacinhydrochlorid (monohydrat) - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - ciprofloxacinhydrochlorid, vandfrit - filmovertrukne tabletter - 250 mg